Through week 12, the frequency of AEs of special interest (AESIs) in the UPA 15 mg group was generally similar compared with the PBO group, with the exception of serious infection, HZ, hepatic disorder, neutropenia, and creatine phosphokinase (CPK) elevation, which were reported in a higher percentage of patients in the UPA 15 mg group (Table 3). The gene discussed is PIK3C2A; the disease is infection.